STUDY DESIGN The anti-interleukin-5 receptor α (anti-IL-5α) monoclonal antibody (mAb), benralizumab, had been approved for the treatment of severe eosinophilic asthma offering significant improvements in exacerbation rates, maintenance oral corticosteroid (mOCS) use, and other asthma outcomes in ph

As-needed (PRN) inhaled corticosteroids (ICS)/formoterol is a novel reliever therapy for patients with mild asthma, providing clinical benefits such as reducing the risks of ICS-related systemic effects in populations with short-acting β2-agonist (SABA) reliever overuse and non-adherence to ICS-based maintenance therapy.¹

In general, there is a lack of an easy method for assessing asthma management, in terms of considering the risk of exacerbation and symptom impairment, as well as accounting for how asthma affects the daily life of patients.1 To address this issue, a simple 10-item yes/no tool named the Asthma Impai

The global prevalence of asthma was as high as 262 million cases, causing 461,000 deaths in 2019.1 Early identification and primary prevention of asthma in young children are crucial to lowering mortality and morbidity caused by this condition.2 The currently used predictive tools for asthma, such a

  Asthma is a serious health problem among children, young people died of asthma from time to time. Clarifying the severity of asthma regarding acute exacerbation and control are the target of asthma management. In the 2022 updates of Global Initiative for Asthma (GINA) guidelines, severity cha

Learn more about the severity and the control of pediatric asthma and the latest GINA guidelines recommendation on the management of asthma in children and adolescents with the proven benefits of tiotropium on severe asthma.

In the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting regarding asthma, Dr. William Anderson, Associate Professor of Pediatrics at the Children’s Hospital Colorado and the University of Colorado, the United States, discussed electronic medication monitoring (EMM) as part of the session entitled “Improving Adherence Outcomes for the Difficult-to-Treat Asthma Patient”.¹